Omicron BA.1 and BA.2 Neutralizing Activity Following Pre-Exposure Prophylaxis with Tixagevimab plus Cilgavimab in Vaccinated Solid Organ Transplant RecipientsAndrew H. Karaba, William A. Werbel, Casey Hussey et al.|medRxiv|2022Cited by 21
Incidence and Severity of COVID-19 Among Vaccinated Solid Organ Transplant Recipients During the Omicron WaveJennifer L. Alejo, William A. Werbel, Teresa Po‐Yu Chiang et al.|Transplantation|2022Cited by 12
Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipientsAndrew H. Karaba, William A. Werbel, Jake D. Kim et al.|American Journal of Transplantation|2023Cited by 12
Anti‐spike antibody durability after <scp>SARS‐CoV</scp>‐2 vaccination in adolescent solid organ transplant recipientsJohn McAteer, Douglas Mogul, Divya Kalluri et al.|Pediatric Transplantation|2024Cited by 3
Omicron Infections in Vaccinated Pediatric Solid Organ Transplant RecipientsJohn McAteer, Douglas Mogul, Divya Kalluri et al.|Journal of the Pediatric Infectious Diseases Society|2023Cited by 1